Process for screening for malignant tumors by determining the amount of GlcNAc transferase V activity
US5605807A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Sep 13, 1994 |
| Grant date | Feb 25, 1997 |
| Priority date | — |
| Expiry date | Sep 13, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S436/827
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A process is provided for screening for a malignant tumor. The process comprises the steps of determining the amount of GlcNAc transferase V activity in a tumor sample by reacting the GlcNAc transferase V in a tumor sample with an acceptor substrate and a sugar nucleotide donor to produce a detectable change, and detecting the change. The acceptor substrate is an oligosaccharide, a glycopeptide or a glycoprotein having the structure GlcNAc .beta.1-2Man .alpha.1-6Man-R.sub.1. R.sub.1 is GlcNAc .beta.1-4GlcNAc with or without fucose or a synthetic linker. The sugar nucleotide donor is uridine diphospho-N-acetylglycosamine. The amount of GlcNAc transferase V activity in the sample is thereby determined. A determination of the malignancy of the tumor is made by comparing the amount of GlcNAc transferase V activity in the sample with an amount of GlcNAc transferase V associated with normal tissues or with known malignant tumors. A diagnostic kit for screening for a malignant tumor is provided. The kit comprises an acceptor substrate and a sugar nucleotide donor to interact with GlcNAc transferase V in a tumor sample to produce a detectable change, and means for detecting the change.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.